MedTrace Logo

Ischemia Modified Albumin in Traumatic Brain Injury

NCT03637101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2019-01-15

No results posted yet for this study

Summary

In the current study the investigators intend to evaluate the role of Ischemia modified albumin (IMA) in the prediction of poor outcome in patients with traumatic brain injury (TBI). The investigators hypothesize that IMA will be elevated in patients with traumatic brain injury due to the excessive production of reactive oxygen species by the injured brain.

Conditions

Interventions

DIAGNOSTIC_TEST

Ischemia modified albumin (IMA)

Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic

Sponsors & Collaborators

  • Kasr El Aini Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-15
Primary Completion
2018-12-07
Completion
2018-12-07

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03637101 on ClinicalTrials.gov